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Summary
Historically, an increase in the percentage and number of circulating pro-
lymphocytes in chronic lymphocytic leukaemia (CLL) has been associated
with strong expression of surface immunoglobulin, trisomy 12 and a poor
outcome. This study re-examines the biological and clinical significance of
increased peripheral blood prolymphocytes in 508 patients at entry into the
randomized UK Leukaemia Research Fund CLL4 trial. It also investigates
the associations between increased prolymphocytes and a comprehensive
array of biomarkers. 270 patients (53%) had <5% prolymphocytes, 167
(33%) had 5–9%, 60 (12%) had 10–14% and 11 (2%) had ≥15% prolym-
phocytes. We show that a higher proportion of prolymphocytes (≥10%)
was independently associated with NOTCH1 mutations (P = 0006),
absence of 13q deletion (P = 0001), high CD38 expression (P = 002) and
unmutated IGHV genes (P = 001). Deaths due to Richter syndrome were
significantly more common amongst patients who had ≥10% vs <10% pro-
lymphocytes (13% vs 2%) respectively (P < 00001). ≥10% prolymphocytes
was also associated with a shorter progression-free survival (Hazard ratio
[HR] 150 [95% confidence interval [CI]: 116–193], P = 0002) and over-
all survival (HR 199 [95% CI: 153–259], P < 00001). Our data support
the routine examination of blood films in CLL and suggest that a finding
of an increased proportion of prolymphocytes may be a trigger for further
evaluation of clinical and laboratory features of progressive disease.
Keywords: Chronic lymphocytic leukaemia, prolymphocytes, prognostic
markers, molecular markers, morphology.
Although peripheral blood lymphocytes in chronic lympho-
cytic leukaemia (CLL) are typically small with clumped chro-
matin and scanty cytoplasm, it has long been recognized that
a subset of patients present with, or acquire, an increased
percentage of lymphocytes that are larger with more abun-
dant cytoplasm, nuclear irregularities, lymphoplasmacytoid
features and/or one or more prominent nucleoli.
Early studies evaluating the clinical significance of lym-
phocyte morphology were confounded by difficulties in dis-
tinguishing CLL from other chronic lymphoproliferative
disorders and gave disparate results (Peterson et al, 1975;
Dubner et al, 1978). However, following the initial observa-
tion that increasing refractoriness to treatment may be
accompanied by the appearance of prolymphocytes in the
blood (Enno et al, 1979), a detailed analysis of 300 cases with
either CLL (n = 258) or B-cell prolymphocytic leukaemia
(PLL) (n = 42) identified >55% circulating prolymphocytes
as a defining diagnostic criterion for PLL, and CLL cases
with 11–55% circulating prolymphocytes (CLL/PL) as having
clinical features intermediate between typical CLL and pro-
lymphocytic leukaemia; namely a higher incidence of spleno-
megaly and higher intensity of surface immunoglobulin
expression (SmIg) than in typical CLL (Melo et al, 1986).
Within the CLL/PL group, those patients with an absolute
prolymphocyte count of ≥15 9 109/l were shown to have a
shorter overall survival (OS) than those with a lower absolute
prolymphocyte count (Melo et al, 1987).
Although the adverse prognostic significance of increased
prolymphocytes was subsequently confirmed in other studies
(Scott et al, 1987; Vallespı et al, 1991; Criel et al, 1997;
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Oscier et al, 1997), the role of morphological examination of
blood films in CLL as a guide to prognosis has diminished
with the discovery of multiple newer biomarkers.
The Leukaemia Research Fund (LRF) CLL4 trial random-
ized previously untreated patients to either chlorambucil or
fludarabine, alone or in combination with cyclophosphamide
(FC) (Catovsky et al, 2007). At randomization, differential
white blood cell counts were performed and this has pro-
vided an opportunity to re-evaluate both the prognostic sig-
nificance of nucleolated cells (prolymphocytes and
immunoblasts) regarding progression-free survival (PFS) and
OS as well as their correlation with established and recently
identified prognostic markers. We found that increased pro-
lymphocytes were associated with markers of poor prognosis
and predicted a shorter PFS and OS.
Patients and methods
In the LRF CLL4 trial 777 patients were randomized between
February 1999 and October 2004 to receive chlorambucil,
fludarabine or FC. The patients were previously untreated,
25% having Binet stage A-progressive disease, 45% stage B
and 30% stage C. The male:female ratio was 3:1 and the
median age was 65 years (range 35–86 years). Clinical fol-
low-up was to 31 October 2010, and follow-up for OS for
UK patients was to January 2015 (median 118 years; range
102–159 years). In the UK, the deaths of CLL trial patients
are flagged and reported to the Clinical Trial Service Unit at
Oxford. For 44 surviving patients resident outside the UK,
for whom this information was not available, OS was cen-
sored at 31 October 2010.
Differential white blood cell counts were performed on
slides stained with May Grunwald Giemsa from blood samples
taken at trial entry in 508 patients. A total of 200 cells were
scored in patients with lymphocyte counts below 25 9 109/l
and 300 cells in the remaining cases. Lymphoid cells were clas-
sified according to the criteria of Melo et al (1986). Specifi-
cally, prolymphocytes were defined as large cells (>2
erythrocytes) with clumped chromatin, a large prominent
vesicular nucleolus and usually abundant cytoplasm. Immuno-
blasts were larger (>3 erythrocytes) with finely dispersed chro-
matin, large and usually >1 nucleoli, and deeply basophilic
cytoplasm (Fig 1). When present, immunoblasts were rare and
were included within the prolymphocyte count.
The choice of cut-off to define an increase in prolympho-
cytes was based on previous studies of the clinical and bio-
logical features of CLL cases with increased prolymphocytes.
To determine associations with other variables a 10% cut-off
was used, as this defines the distinction between CLL and
CLL/PL. To evaluate the impact on clinical outcome, both a
10% cut-off and an absolute prolymphocyte count of
≥15 9 109/l were used, as the latter was found to be the best
discriminator of outcome within CLL/PL (Melo et al, 1987).
The clinical value of a 10% cut-off was also confirmed in
our analysis of PFS and OS (see results).
Immunophenotypic analysis was performed centrally by
flow cytometry using a panel of monoclonal antibodies:
CD5, CD19, CD20, CD23, CD79b, FMC7, and surface light
chain immunoglobulins, enabling a CLL score to be derived
(Moreau et al, 1997). All cases with a low score were also
reviewed. Those cases with a phenotype lacking expression of
CD23 or CD5, probably reflecting prolonged transit in the
postal system or an alternative diagnosis, were only included
if lymphocyte morphology was typical of CLL and fluores-
cent in situ hybridization (FISH) for t(11;14) was negative,
particularly in CD23 negative cases. Data on the following
(A) (B)
(C) (D)
Fig 1. Morphological appearances of chronic
lymphocytic leukaemia (CLL) and CLL with
>10% circulating prolymphocytes (CLL/PL).
(A) Typical CLL. The majority of cells are
small with clumped chromatin. (B) Typical
CLL/PL. There is a mixture of prolymphocytes
and typical CLL lymphocytes. (C) Typical CLL/
PL showing small lymphocytes, prolympho-
cytes and an immunoblast. (D) Typical B-cell
prolymphocytic leukaemia (B-PLL). The
majority of cells have condensed non-clumped
chromatin and a single vesicular nucleolus.
This panel is shown here for comparative pur-
poses only, to illustrate the similar morphology
of the prolymphocytes in B-PLL to those seen
in panels B and C. The majority of cells in B-
PLL are prolymphocytes and no small lympho-
cytes are seen. The usual “CLL score” is 0–1.
B-PLL is a distinct disorder and does not arise
from a pre-existing CLL. Magnification: panels
A, B and C 9100; panel D 960.
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markers were available: FISH to detect 11q, 13q, 17p dele-
tions and trisomy 12, IGHV mutation status, CD38, ZAP70
and CLLU1 expression, serum beta-2 microglobulin (B2M),
TP53, SF3B1 and NOTCH1 mutations and telomere length
as reported elsewhere, together with a full description of the
cut-offs used to define positivity (Oscier et al, 2010, 2013;
Gonzalez et al, 2011, 2013; Strefford et al, 2015).
The LRF CLL4 trial was registered as an International
Standard Randomized Trial, number ISRCTN58585610 and
was approved by a UK multicentre research ethics commit-
tee. The trial followed the UK Medical Research Council
guidelines for good clinical practice. All patients provided
written informed consent. All authors had access to the pri-
mary clinical trial data. The main trial endpoints have been
previously reported (Catovsky et al, 2007).
Survival was estimated by the Kaplan-Meier method. OS
was calculated from randomization to death from any cause.
PFS was estimated from the time of randomization to relapse
needing further treatment, progression or death from any
cause. For non-responders (NR) and those with progressive
disease (PD), date of progression was when NR/PD was
recorded. Multivariate analyses were performed by means of
stepwise generalized linear modelling and the Cox propor-
tional hazards model. Values of P ≤ 005 (two sided) were
considered significant. Analyses were performed using the
STATISTICA software from StatSoft, a subsidiary of Dell,
Inc. (Tulsa, OK, USA).
Results
Of 508 assessable patients, 270 (53%) had <5% prolympho-
cytes, 167 (33%) had 5–9%, 60 (12%) had 10–14% and 11
(2%) had ≥15% prolymphocytes. Among the 504 patients in
whom an absolute lymphocyte count was available, the abso-
lute prolymphocyte count was <15 9 109/l in 442 (88%) and
≥15 9 109/l in 62 (12%) patients. These groups were equally
distributed between the three trial arms. There was a ten-
dency for younger patients, those with stage B disease, a low
white blood count, 11q deletion or high CLLU1 expression
to be moderately under-represented amongst the 508 trial
patients who had prolymphocyte data, but otherwise the
clinical and molecular characteristics of this subset were the
same as those of the 269 patients without available prolym-
phocyte data (Table SI). Thus the subset with prolymphocyte
data was broadly representative of the trial as a whole.
Association of increased prolymphocytes with
immunophenotype
Eighty-eight per cent of patients had a CLL score of 4 or 5
and 7% had a score of 3. There was no correlation between
the CLL score and the percentage of prolymphocytes. How-
ever there was a significant association between ≥10% pro-
lymphocytes and strong expression of SmIg (P < 00001).
There was no association between a higher proportion of
prolymphocytes and any of the other immunophenotypic
markers that comprise the CLL score (Table I).
Association of increased prolymphocytes with other
clinical and laboratory features
Table II summarizes the degree of association between ≥10%
prolymphocytes and other clinical and laboratory features.
No associations were found with treatment arm, age, Binet
stage, the presence of lymphadenopathy or splenomegaly,
TP53 deletion or mutation, deletion of 11q, SF3B1 mutation
or ZAP70 expression. Because the variables were available in
different sub-sets of patients, multivariate analysis of the sig-
nificant variables was performed in consecutive stages, begin-
ning with only the variables that were available from the
majority (n = 460) of the 508 patients with prolymphocyte
data. Absolute prolymphocyte count was not included
because of its close relationship, by definition, to % prolym-
phocytes. Gender, white blood count, 13q deletion and tri-
somy 12 were each independently significant in this first
stage. We then modelled the other significant variables
(Table II) one at a time together with the above four vari-
ables. Those which retained independent significance were
taken forward to a final model (n = 256) which included
gender, white blood cell count, IGHV mutation status, 13q
deletion, trisomy 12, NOTCH1 mutation and CD38 expres-
sion. Four variables were independently associated with per-
centage of prolymphocytes (Table III).
Association of increased prolymphocytes with outcome
There was no significant difference in first-line overall
response rate (74% vs 80%, P = 03) or first line CR rate
Table I. The association between the proportion of prolymphocytes
and the CLL score components (atypical phenotypes are shown in
bold).
CLL score
component
Patients
(n)
≥10%
prolymphocytes
(%)
≥15%
prolymphocytes
(%)
P-value
(≥10%)
FMC7 negative 403 59 (15) 7 (2) NS
FMC7 positive 91 10 (11) 3 (3)
SmIg weak 371 37 (10) 5 (1) <00001*
SmIg strong 123 32 (26) 5 (4)
CD23 positive 462 67 (145) 10 (2) NS
CD23 negative 32 2 (6) 0 (0)
CD79b weak 437 59 (135) 9 (2) NS
CD79b strong 57 10 (18) 1 (2)
CD5 positive 490 69 (14) 10 (2) NS
CD5 negative 4 0 (0) 0 (0)
CLL, chronic lymphocytic leukaemia.
*When CD5-negative and CD23-negative cases are excluded, the
relationship between surface immunoglobulin (SmIg) expression and
≥10% proplymphocytes remains (10% weak vs 27% strong;
P < 00001).
Prolymphocytes in CLL
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(17% vs 18%, P = 09) for patients with ≥10% vs <10% pro-
lymphocytes respectively.
PFS following initial treatment was worse for patients with
≥10% prolymphocytes (Hazard ratio [HR] 150 [95%
confidence interval (CI): 116–193], P = 0002) (Fig 2A) and
for those with ≥15 9 109/l prolymphocytes (HR 145 [95%
CI: 111–191], 0007) (Fig 2B). The 5-year PFS was 4%
(95% CI: 0–9%) for patients with ≥10% prolymphocytes vs
Table II. The association of baseline demographic and molecular categorical variables with % prolymphocytes (cut-off 10%).
Variable Assessable patients (n) ≥10% prolymphocytes (%) P-value§
Randomized first-line treatment** Chlorambucil 256 34 (13) NS
Fludarabine 127 22 (17)
FC 125 15 (12)
Gender** Female 137 11 (8) 002
Male 371 60 (16)
Age group (years) <60 154 20 (13) NS
60–69 201 26 (13)
70+ 153 25 (16)
Disease stage (Binet) A progressive 139 18 (13) NS
B 216 35 (16)
C 153 18 (12)
Splenomegaly No 221 26 (12) NS
Yes 287 45 (16)
Lymphadenopathy No 85 12 (14) NS
Yes 423 59 (14)
White blood cell count (cut-off 100 9 109/l)** Low 256 26 (10) 002
High 246 43 (17)
IGHV mutation status (cut-off 98%*)** Mutated 163 10 (6) <00001
Unmutated 257 53 (21)
b-2 microglobulin (cut-off 4 mg/l*)** Low 201 19 (9) 0004
High 169 34 (20)
TP53 deletion (cut-off 10%*) or mutation No 426 60 (14) NS
Yes 41 9 (22)
11q deletion No 380 59 (16) NS
Yes 86 9 (10)
13q deletion** No 195 43 (22) 00001
Yes 271 25 (9)
Trisomy 12** No 389 47 (12) 00006
Yes 77 21 (27)
NOTCH1 mutation** No 327 39 (12) <00001¶
Yes 39 16 (41)
SF3B1 mutation No 284 43 (15) NS
Yes 60 13 (22)
CLLU1 expression (cut-off RQ 40†)** Low 203 17 (8) 00002
High 194 42 (22)
CD38 expression (cut-off 7%*)** Negative 163 5 (3) <00001
Positive 257 54 (21)
ZAP70 expression (cut-off 10%*) Negative 191 22 (12) NS
Positive 179 31 (17)
Telomere length‡** Long 79 4 (5) 0009
Intermediate 79 13 (16)
Short 146 30 (21)
Absolute prolymphocyte count ≥15 9 109/l No 442 33 (7) <00001¶
Yes 62 36 (58)
FC, fludarabine with cyclophosphamide.
*Oscier et al (2010)
†Gonzalez et al (2013); RQ – real time relative quantification
‡Cut-offs defined in Strefford et al (2015)
§Chi-squared test.
¶≥15% vs <15% prolymphocytes also significant: Notch1 P = 0002; absolute prolymphocyte count P < 00001
**Included in multivariate analysis
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17% (14–21%) for those with <10% prolymphocytes. OS was
also worse for patients with ≥10% prolymphocytes (HR 199
[95%CI: 153–259], P < 00001) (Fig 2C), and for those
with ≥15 9 109/l prolymphocytes (HR 153 [95% CI: 115 –
204], P = 0004) (Fig 2D). OS at 10 years was 3% (0–7%)
vs 30% (26–35%) for patients with ≥10% vs <10% prolym-
phocytes respectively. The adverse prognostic significance of
≥10% prolymphocytes for both PFS and OS was evident in
each arm of the trial (Figure S1).
Given that the choice of a 10% cut-off to define increased
prolymphocytes was based on historical data, we then com-
pared the PFS and OS for each of four groups defined by %
prolymphocytes ranging from <5% to ≥15% (Fig 3). This
shows a significant reduction in both PFS and OS compared
to cases with <5% prolymphocytes, irrespective of whether
the cut-off was 5% (PFS P = 00004, OS P = 00006) or 10%
(PFS P = 0006, OS P < 00001), but provides no support
for a cut-off of >15% (PFS P = 03, OS P = 007) which rep-
resents only 2% of cases.
Only 8/71 (11%) patients with ≥10% prolymphocytes
received no further treatment during the clinical follow-up
period of the trial (median 7 years, range 6–12 years) com-
pared with 146/437 (33%) of those with <10% prolympho-
cytes (P = 00002). Two or more further lines of treatment
were given to 37/71 (52%) patients with ≥10% prolympho-
cytes, but to only 134/437 (31%) patients with <10% pro-
lymphocytes (P = 00004).
To date 17/508 patients (3%) have died as a result of
Richter syndrome. Such deaths were significantly more com-
mon amongst patients who had ≥10% prolymphocytes at
randomization (9/71, 13%) vs those with <10% prolympho-
cytes (8/437, 2%; P < 00001).
As with the analysis of factors associated with % prolym-
phocytes, the multivariate analysis to determine whether %
prolymphocytes was independently associated with survival
was carried out in three stages, using Cox regression analysis.
≥10% prolymphocytes was an independent predictor of PFS
in the first-stage model (n = 465), as were also randomized
treatment, gender, 11q deletion and TP53 deletion/mutation.
Adding in the variables from the smaller subsets one at a
time, ≥10% prolymphocytes remained an independent pre-
dictor of PFS when, in addition to the above first-stage vari-
ables, the model also included any one of the following:
ZAP70, NOTCH1, SF3B1 or telomere length, but not when it
included any of IGHV mutational status, B2M, CD38 or
CLLU1 expression. When all the significant variables from
the second stage were included together in a final model
(n = 120), % prolymphocytes was no longer an independent
predictor of PFS.
≥10% prolymphocytes was an independent predictor of
OS in the first-stage model (n = 465), as were also disease
stage, age, 11q and 13q deletion, and TP53 deletion/muta-
tion. Adding in the variables from the smaller subsets one at
a time, ≥10% prolymphocytes remained an independent pre-
dictor of OS when, in addition to the above first-stage vari-
ables, the model also included any one of the following:
IGHV mutational status, B2M, CD38, ZAP70 or CLLU1
expression, NOTCH1 or SF3B1 mutations or telomere length.
When all the significant variables from the second stage were
included together in a final model (n = 121), % prolympho-
cytes was no longer an independent predictor of OS.
Discussion
This is the first study to evaluate the clinical significance of
increased circulating prolymphocytes in CLL within the con-
text of a randomized chemotherapy trial and demonstrates
that ≥10% prolymphocytes and an absolute prolymphocyte
count of ≥15 9 109/l are associated with a shorter PFS and
OS in univariate analysis. Independent significance of ≥10%
prolymphocytes is lost in multivariate analysis, although it
retains significance for OS in models that include either
IGHV mutational status or B2M, which we previously
showed to be independent markers of outcome in the LRF
CLL4 trial (Oscier et al, 2010). We also noted that patients
with ≥10% prolymphocytes were significantly more likely to
require second or third line treatments and to die from Rich-
ter transformation, although the latter observation requires
confirmation in a larger study.
We were able to confirm in this large cohort of patients
the previously documented associations between increased
prolymphocytes, strong expression of SmIg and trisomy 12,
and, for the first time, we document associations with male
gender, elevated B2M, unmutated IGHV genes, high CD38
and CLLU1 expression, short telomere length, NOTCH1
mutations and absence of 13q deletion. Interestingly, and not
expected, in a multivariate analysis only unmutated IGHV
genes, high CD38 expression, NOTCH1 mutations and
absence of 13q deletion, but not trisomy 12, were indepen-
dently associated with ≥10% prolymphocytes. The association
Table III. Variables associated with ≥10% pro-
lymphocytes in multivariate analysis. Variable Odds Ratio Lower 95% CL Upper 95% CL P
NOTCH1 mutation 3.88 1.46 10.30 0.006
Absence of 13q deletion 4.41 1.82 10.69 0.001
Positive CD38 expression 6.48 1.44 29.25 0.02
Unmutated IGHV genes 5.02 1.39 18.17 0.01
CL, confidence limit.
Prolymphocytes in CLL
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with NOTCH1 mutations may become stronger once samples
are screened for 30 non-coding mutations (Puente et al,
2015).
Melo et al (1986) raised the question as to ‘whether the
phenomenon of prolymphocytoid transformation in CLL
represents the release into the peripheral blood of cells in the
mitotic phase of the cell cycle, or whether the prolympho-
cytes belong to a subclone with a growth advantage’. With
regard to the first possibility, it has subsequently become
clear that CLL cells recirculate between secondary lymphoid
organs and peripheral blood and the latter contains subpop-
ulations of resting or recently proliferating CLL cells which
differ in their expression of surface receptors such as CD38,
CD5 and CXCR4.(Calissano et al, 2011; Cuthill et al, 2015).
Within secondary lymphoid organs, CLL cells divide within
proliferation centres composed both of tumour cells and
components of the tissue microenvironment, such as T cells,
monocyte-derived nurse like cells and stromal cells, with
which they interact. (Herishanu et al, 2011; ten Hacken &
Burger, 2014). Tumour cells within proliferation centres con-
tain medium-sized and large lymphoid cells comprising pro-
lymphocytes and immunoblasts whose histological features
mirror the morphology of circulating prolymphocytes and
immunoblasts (Herreros et al, 2010). Immunohistochemical
studies show that the large tumour cells within proliferation
centres show increased expression of Ki67, CD20, CD23,
CD38, IRF4, survivin (BIRC5), BCL2 and MYC compared to
small lymphocytes outside proliferation centres, and upregu-
late NOTCH, CD40 and BAFF signalling pathways leading to
NF-kB activation (Patten et al, 2008; Gine et al, 2010; Her-
reros et al, 2010; Gibson et al, 2015; Onaindia et al, 2015).
Gine et al (2010) studied tissue biopsies, mainly from lymph
nodes, in 100 CLL patients of whom 73% had suspected
Richter transformation. Twenty-eight per cent had expanded
or confluent proliferation centres, which were associated with
short survival. Ciccone et al (2012) noted a similar associa-
tion between confluent proliferation centres and short sur-
vival in a study of lymph node biopsies in 183 CLL patients.
Neither of these studies reviewed lymphocyte morphology in
the peripheral blood but, if the emergence of prolymphocytes
into the blood represents the egress of cells from prolifera-
tion centres with a similar morphological appearance, then
both a raised prolymphocyte count and an increase in a sub-
population with the immunophenotype of proliferating cells
would be anticipated in these cases.
There are no data to confirm the second possibility that
prolymphocytes represent a subclone. However, FISH anal-
ysis of proliferation centres and their surrounding areas of
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small lymphocytes showed a higher incidence of copy
number abnormalities within the proliferation centres
(Balogh et al, 2011). More recently, screening of concur-
rent blood and lymph node samples for genomic muta-
tions and copy number chromosomal abnormalities
identified cases with clonal driver mutations within lymph
nodes that were only detected in the blood as small circu-
lating subclones (Del Giudice et al, 2016). This supports
the concept that mutations arise within a proliferative tis-
sue compartment and raises the possibility that the circu-
lating subclones may be enriched within cells with a
‘proliferative’ immunophenotype and/or those with prolym-
phocytic morphology.
The association between increased prolymphocytes and
NOTCH1 mutations is a novel and unexpected finding. Cir-
culating CLL cells with trisomy 12 have increased expression
of the surface integrins CD11a, CD11b and CD18, which are
down-regulated in the presence of NOTCH1 mutations
(Riches et al, 2014). The rare cases of CLL with a MYC
translocation (Huh et al, 2008; Put et al, 2012) have been
shown to be associated with increased circulating
prolymphocytes and although speculative, it is possible that
these genomic abnormalities could facilitate the exit of pro-
lymphocytes into the peripheral blood.
Regardless of the biology of prolymphocytes and the rea-
sons for their appearance in the peripheral blood, our study
confirms and extends earlier reports of their adverse prog-
nostic significance. Although flow cytometric analysis has
become an essential tool in the diagnostic evaluation of CLL
and morphological expertise is less widespread, the distinc-
tion between cells with or without prominent nucleoli in a
well-made blood film is relatively straightforward. Moreover,
we noted that even ≥5% prolymphocytes were associated
with a poorer outcome, and the higher cut-offs used in this
study to define increased prolymphocytes clearly distinguish
cases with typical morphology from those with CLL/PL.
Depending on the clinical context, increased prolymphocytes
at diagnosis or during the course of the disease may be a
harbinger of progressive disease and may warrant further
clinical and laboratory evaluation.
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